Palvella Therapeutics (PVLA) Operating Leases (2019 - 2026)

Palvella Therapeutics (PVLA) has reported Operating Leases for 7 consecutive years, with $375000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases changed N/A year-over-year to $375000.0; the TTM figure through Mar 2026 stood at $375000.0 (changed N/A YoY), while the FY2025 annual figure was $431000.0, changed N/A from the prior year.
• Operating Leases slipped to $375000.0 in Q1 2026 per PVLA's latest filing, from $431000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $14.4 million in Q1 2022 and bottomed at $375000.0 in Q1 2026.
• Historically, Operating Leases has averaged $9.6 million across 4 years, with a median of $12.2 million in 2022.
• Annual changes were most pronounced in 2022 — Operating Leases fell 15.42% — and 2023, when it retreated 10.05%.
• Palvella Therapeutics' Operating Leases stood at $12.2 million in 2022, then dropped by 2.66% to $11.9 million in 2023, then tumbled by 96.38% to $431000.0 in 2025, then dropped by 12.99% to $375000.0 in 2026.
• Business Quant data shows PVLA's Operating Leases at $375000.0 in Q1 2026, $431000.0 in Q4 2025, and $11.9 million in Q2 2023.